Immuron (ASX:IMC) recorded a 13% quarterly increase in the global sales of its immune supplement, Travelan, in the September quarter, according to a Tuesday filing with the Australian bourse.
Sales of Travelan in Australia increased 3% to AU$1 million in the September quarter from AU$983,000 in the three months to June. North American sales climbed 48% to AU$456,000 from AU$309,000 in the June quarter.
The biopharmaceutical company's shares were up nearly 4% in recent Tuesday trade.
Price (AUD): $0.09, Change: $+0.003, Percent Change: +3.66%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。